BIOYF (Biosyent) FFO per Share


BIOYF Biosyent Inc BIOYF
98 GF Score
Price $10.28
GF Value $11.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Biosyent FFO per Share?

FFO per Share only applies to REITs.

BIOYF
98GF Score
Biosyent Inc BIOYF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biosyent (BIOYF) Overvalued in 2026?

Based on GuruFocus' analysis, Biosyent stock appears to be undervalued. The current stock price of $10.28 is trading 11.9% below its estimated GF Value™ of $11.67. GuruFocus considers Biosyent to be Modestly Undervalued.

Key valuation signals for BIOYF:

  • FFO per Share:
  • GF Value™: $11.67 vs. price of $10.28 (11.9% below fair value)
  • GF Score™: 98/100 with 4 warning signs

No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosyent Business Description

Other Exchanges RX:Canada
Address 2476 Argentia Road, Suite 402, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score

Get the complete analysis for BIOYF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.28
Price
$11.67
GF Value